November 4-5, 2013 | Boston Marriott Cambridge | Cambridge, MA
Personalized Medicine has the potential to optimize healthcare by allowing individual patients to receive earlier diagnosis and risk assessment, followed by tailored therapy with best response and minimum toxicity. The pharmaceutical industry has the opportunity to develop drugs that are targeted to sub-populations of responders, which may have otherwise failed a trial in the general population. However, while the concept of personalized medicine is promising, implementation is proving challenging. Cambridge Healthtech Institute’s Fifth Annual Personalized Medicine meeting addresses value creation and ROI models, strategies for co-development of drugs and diagnostics, clinical trial designs for personalized medicine, and implementation barriers related to IP, regulatory, and reimbursement issues.
- Strategies for companion diagnostic development
- Value creation models in personalized medicine
- Case studies in drug-diagnostic co-development
- Implementing personalized medicine at big pharma
- Biomarkers for patient selection
- Impact of personalized medicine on clinical trial design
- Regulatory and reimbursement issues
Scientists who wish to present their knowledge and expertise to their colleagues are asked to submit an abstract. Remember to specify the conference that you are interested in and please provide your full contact information.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.
If you are interested in presenting, please click here to submit your proposal.
Deadline for submission is Friday, May 3, 2013
For more information, please contact:Julia Boguslavsky
Executive Director, Conferences
For sponsorship information, please contact:Ilana Quigley
Manager, Business Development